Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols.

PURPOSE: To define prognostic factors for response and long-term outcome for a wide spectrum of osteosarcomas, extending well beyond those of the typical young patient with seemingly localized extremity disease. PATIENTS AND METHODS: A total of 1,702 consecutive newly diagnosed patients with high-grade osteosarcoma of the trunk or limbs registered into the neoadjuvant studies of the Cooperative Osteosarcoma Study Group before July 1998 were entered into an analysis of demographic, tumor-related, and treatment-related variables, response, and survival. The intended therapeutic strategy included preoperative and postoperative chemotherapy with multiple agents as well as surgery of all operable lesions. RESULTS: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis. Actuarial 10-year overall and event-free survival rates were 59.8% and 48.9%. Among the variables assessable at diagnosis, patient age (actuarial 10-y...

[1]  S. Ferrari,et al.  Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity: an analysis of 300 patients treated at the Rizzoli Institute. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  S. Ferrari,et al.  Delay in Diagnosis of High-Grade Osteosarcoma of the Extremities. Has it any Effect on the Stage of Disease? , 2000, Tumori.

[3]  C. Coltman,et al.  Underrepresentation of patients 65 years of age or older in cancer-treatment trials. , 1999, The New England journal of medicine.

[4]  R. Grimer,et al.  Osteosarcoma of the pelvis. , 1999, The Journal of bone and joint surgery. British volume.

[5]  A. Huvos,et al.  Expression of HER2/erbB-2 correlates with survival in osteosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Arndt,et al.  Common musculoskeletal tumors of childhood and adolescence. , 1999, The New England journal of medicine.

[7]  U. Göbel,et al.  Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten , 1999 .

[8]  S. Bielack,et al.  Combined modality treatment for osteosarcoma occurring as a second malignant disease. Cooperative German-Austrian-Swiss Osteosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Winkelmann,et al.  Malignant tumor of the distal part of the femur or the proximal part of the tibia: endoprosthetic replacement or rotationplasty. Functional outcome and quality-of-life measurements. , 1999, The Journal of bone and joint surgery. American volume.

[10]  F. Sim,et al.  High grade surface osteosarcoma , 1999, Cancer.

[11]  S. Ferrari,et al.  Neoadjuvant chemotherapy for osteosarcoma of the extremity in patients in the fourth and fifth decade of life. , 1998, Oncology reports.

[12]  S. Bielack,et al.  Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Huvos,et al.  Osteosarcoma of the Pelvis: Oncologic Results of 40 Patients , 1998, Clinical orthopaedics and related research.

[14]  S. Ferrari,et al.  Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. , 1998, Journal of chemotherapy.

[15]  S. Ferrari,et al.  Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Souhami,et al.  Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup , 1997, The Lancet.

[17]  O. Monge,et al.  Prognostic factors in bone sarcomas. , 1997, Acta orthopaedica Scandinavica. Supplementum.

[18]  R Maas,et al.  Tumor size and prognosis in aggressively treated osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Terrier,et al.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Bielack,et al.  Osteosarcoma: relationship of response to preoperative chemotherapy and type of surgery to local recurrence. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  P. Picci,et al.  Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. , 1995, The New England journal of medicine.

[22]  P. Kaatsch,et al.  Zweitmalignome nach malignen Erkrankungen im Kindesalter , 1995 .

[23]  P. Picci,et al.  Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  S. Ferrari,et al.  Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities. , 1994, Journal of chemotherapy.

[25]  A. Davis,et al.  Prognostic factors in osteosarcoma: a critical review. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  S. Ferrari,et al.  Primary chemotherapy and delayed surgery for nonmetastatic osteosarcoma of the extremities. Results in 164 patients preoperatively treated with high doses of methotrexate followed by cisplatin and doxorubicin , 1993, Cancer.

[27]  A. Huvos,et al.  Osteogenic sarcoma with clinically detectable metastasis at initial presentation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  S. Ferrari,et al.  Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy , 1993, Cancer.

[29]  A. Craft,et al.  A comparison of two short intensive adjuvant chemotherapy regimens in operable osteosarcoma of limbs in children and young adults: the first study of the European Osteosarcoma Intergroup. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Krischer,et al.  Interval between symptom onset and diagnosis of pediatric solid tumors. , 1991, The Journal of pediatrics.

[31]  R. Simon,et al.  Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. , 1991, Journal of the National Cancer Institute.

[32]  P. Picci,et al.  Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities the istituto rizzoli experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin , 1990, Cancer.

[33]  H. Mouridsen,et al.  Prognostic factors in osteosarcomas. A regression analysis , 1988, Cancer.

[34]  M. van Glabbeke,et al.  Osteosarcoma of the limbs. Report of the EORTC‐SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation , 1988, Cancer.

[35]  H. Jürgens,et al.  Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Draper,et al.  Incidence of second primary tumours among childhood cancer survivors. , 1987, British Journal of Cancer.

[37]  N. Jaffe,et al.  Weekly high-dose methotrexate and doxorubicin for osteosarcoma: the Dana-Farber Cancer Institute/the Children's Hospital--study III. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[39]  A. Huvos Osteogenic sarcoma of bones and soft tissues in older persons. A clinicopathologic analysis of 117 patients older than 60 years , 1986, Cancer.

[40]  O. Oberlin,et al.  Second malignant neoplasms in children: an update from the Late Effects Study Group. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  W. Ebell,et al.  Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  K. D. Devine,et al.  Osteosarcoma of the jaw , 1983, Cancer.

[43]  J. Ritter,et al.  Kooperative Osteosarkomstudie COSS-77: Ergebnisse nach über 4 Jahren , 1982 .

[44]  G. Rosen,et al.  Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy , 1982, Cancer.

[45]  G. Rosen,et al.  Osteogenic sarcoma: eight-percent, three-year, disease-free survival with combination chemotherapy (T-7). , 1981, National Cancer Institute monograph.

[46]  D. Dahlin Prognostic factors in osteosarcoma. , 1980, International journal of radiation oncology, biology, physics.

[47]  P. Scranton,et al.  Prognostic factors in osteosarcoma: A review of 20 years' experience at the university of pittsburgh health center hospitals , 1975 .

[48]  D. Cox,et al.  The analysis of binary data , 1971 .

[49]  N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[50]  C. H. Price Primary bone-forming tumours and their relationship to skeletal growth. , 1958, The Journal of bone and joint surgery. British volume.

[51]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[52]  O. Schober,et al.  High-Activity Samarium-153-EDTMP Therapy in Unresectable Osteosarcoma , 1999, Nuklearmedizin.

[53]  A. Huvos,et al.  Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  A. Skretting,et al.  Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach. , 1996, Acta oncologica.

[55]  H. Horiuchi,et al.  ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma , 1996, Cancer.

[56]  G Rosen,et al.  Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  M. Krailo,et al.  A randomized study comparing high-dose methotrexate with moderate-dose methotrexate as components of adjuvant chemotherapy in childhood nonmetastatic osteosarcoma: a report from the Childrens Cancer Study Group. , 1987, Medical and pediatric oncology.

[58]  D. Cox Regression Models and Life-Tables , 1972 .